CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 503 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $191,573 | -26.9% | 3,547 | -7.8% | 0.09% | -28.8% |
Q1 2024 | $262,212 | +16.4% | 3,847 | +7.0% | 0.13% | +10.0% |
Q4 2023 | $225,172 | +34.5% | 3,597 | -2.4% | 0.12% | +25.0% |
Q3 2023 | $167,353 | -15.7% | 3,687 | +4.2% | 0.10% | -11.9% |
Q2 2023 | $198,567 | +24.1% | 3,537 | 0.0% | 0.11% | +18.5% |
Q1 2023 | $159,979 | +15.5% | 3,537 | +3.8% | 0.09% | +8.2% |
Q4 2022 | $138,495 | -38.2% | 3,407 | -0.6% | 0.08% | -43.3% |
Q3 2022 | $224,000 | +7.7% | 3,427 | 0.0% | 0.15% | +10.3% |
Q2 2022 | $208,000 | -3.3% | 3,427 | 0.0% | 0.14% | +9.7% |
Q1 2022 | $215,000 | +3.9% | 3,427 | +25.7% | 0.12% | +3.3% |
Q4 2021 | $207,000 | -26.6% | 2,727 | +8.3% | 0.12% | -34.1% |
Q3 2021 | $282,000 | +6.8% | 2,517 | +54.4% | 0.18% | -2.2% |
Q2 2021 | $264,000 | +80.8% | 1,630 | +35.8% | 0.19% | +70.6% |
Q1 2021 | $146,000 | – | 1,200 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |